Michiel S Van Der Heijden

List of Publications by Year
in descending order

35 papers	11,851 citations	361045 20 h-index	395343 33 g-index
36 all docs	36 docs citations	36 times ranked	13386 citing authors

#	Article	IF	Citations
1	TGFÎ² attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018, 554, 544-548.	13.7	3,359
2	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	6.3	3,077
3	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	6.3	1,728
4	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2018, 391, 748-757.	6.3	1,142
5	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. European Urology, 2017, 72, 544-554.	0.9	638
6	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine, 2019, 25, 1706-1714.	15.2	407
7	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nature Medicine, 2020, 26, 1839-1844.	15.2	245
8	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 525-537.	5.1	225
9	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. European Urology, 2016, 69, 384-388.	0.9	177
10	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
11	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology, 2019, 75, 435-444.	0.9	97
12	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 5082-5093.	3.2	82
13	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. Scientific Reports, 2017, 7, 5554.	1.6	73
14	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	5.1	61
15	Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. European Urology, 2021, 80, 7-11.	0.9	60
16	A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. European Urology, 2017, 71, 858-862.	0.9	59
17	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. European Urology, 2022, 82, 212-222.	0.9	56
18	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Medicine, 2019, 11, 60.	3.6	36

#	Article	IF	Citations
19	Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer, 2013, 13, 561.	1.1	27
20	Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome inÂPatients Undergoing Pre-Operative Chemotherapy inÂMuscle-Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 351-360.	0.2	24
21	Defining the Tumor Microenvironment of Penile Cancer by Means of the Cancer Immunogram. European Urology Focus, 2019, 5, 718-721.	1.6	19
22	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. European Urology Oncology, 2021, 4, 456-463.	2.6	18
23	The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. Frontiers in Immunology, 2021, 12, 793964.	2.2	13
24	Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 342.e7-342.e14.	0.8	11
25	Survival after neoadjuvant/induction combination immunotherapy vs combination platinumâ€based chemotherapy for locally advanced (Stage <scp>III</scp>) urothelial cancer. International Journal of Cancer, 2022, 151, 2004-2011.	2.3	11
26	Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. Cancer Treatment and Research Communications, 2020, 25, 100266.	0.7	10
27	Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer. Scientific Reports, 2020, 10, 10952.	1.6	9
28	A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Scientific Reports, 2021, 11, 13683.	1.6	8
29	Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014. European Urology, 2015, 68, e33-e34.	0.9	6
30	Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. European Urology Focus, 2022, 8, 995-1002.	1.6	6
31	The Molecular Background of Urothelial Cancer: Ready for Action?. European Urology, 2015, 67, 202-203.	0.9	5
32	Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer. Journal of Urology, 2019, 201, 478-485.	0.2	4
33	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878.	5.8	3
34	A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, e173-e179.	0.9	1
35	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et alâ€™s Letter to the Editor re: Alfonso GÃ³mez de LiaÃ±o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Antiâ€“PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269â€“76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. European Urology, 2021, 79, e20-e21.	0.9	0